What's Coming: GLP-1 Pipeline 2026–2028

Why the Pipeline Matters Right Now

If you're currently on a GLP-1 medication — or thinking about starting one — you might wonder why future drugs matter. Three reasons:

First, competition drives prices down. Every new entrant gives manufacturers less pricing power. We've already seen this: Zepbound's launch forced Novo Nordisk to cut Wegovy prices, and oral Wegovy launched at $149/month specifically to compete with Eli Lilly's upcoming oral option.

Second, next-gen drugs may be significantly more effective. Retatrutide's 28.7% average weight loss blows past anything currently available. That's nearly double what the first-generation Saxenda achieved.

Third, new formats are coming. Oral pills that don't require fasting protocols, long-acting monthly injections, and combination therapies that address multiple metabolic pathways simultaneously.

Orforglipron — Eli Lilly's Oral Pill

What it is: A once-daily oral GLP-1 receptor agonist — but unlike Rybelsus or oral Wegovy, orforglipron is a non-peptide molecule. That's a significant distinction. Peptide-based oral GLP-1s (like semaglutide pills) require specific fasting protocols because the peptide is fragile and gets destroyed by stomach acid without careful timing. Orforglipron is a small molecule — it doesn't require fasting, doesn't need to be taken with a specific amount of water, and is stable at room temperature (no refrigeration).

The data: The ATTAIN-1 trial showed 12.4% average body weight loss at 72 weeks. That's less than injectable semaglutide (~15%) or tirzepatide (~22.5%), but it's a daily pill with no injection anxiety, no cold-chain storage, and a much simpler dosing protocol than oral Wegovy.

Timeline: Eli Lilly submitted the NDA in late 2025. The FDA decision is expected in late 2026, possibly sooner if orforglipron receives the Commissioner's National Priority Voucher expedited review. Eli Lilly's pricing guidance suggests $149–$399/month depending on dose — directly competing with the Wegovy pill.

Why it matters: Orforglipron could be the first GLP-1 that's as easy to take as a daily vitamin. No fasting, no injection, no refrigeration. That simplicity could dramatically expand the addressable market — particularly among people who would never consider injections.

Retatrutide — The Triple Agonist

What it is: A once-weekly injectable that activates three receptors simultaneously: GLP-1, GIP, and glucagon. Current approved drugs activate one (semaglutide) or two (tirzepatide) of these targets. The glucagon receptor activation is the key differentiator — it increases energy expenditure and drives hepatic fat clearance, adding a calorie-burning component that GLP-1-only drugs don't have.

The data: TRIUMPH-4 (the first Phase 3 trial to report results, December 2025) showed an average of 28.7% body weight loss at 68 weeks at the 12mg dose. To put that in context: that's roughly 71 pounds for a 250-pound person. The trial also showed dramatic improvements in knee osteoarthritis symptoms, with over 75% reduction in pain scores.

Safety signal to watch: Approximately 20.9% of patients on the highest dose reported dysesthesia — skin sensitivity, tingling, or tenderness to touch. It's a novel side effect not seen with current GLP-1 drugs. Generally mild, but it's something the FDA will scrutinize.

Timeline: Seven Phase 3 TRIUMPH trials are running, with primary completion dates throughout 2026. If all go well, Eli Lilly is expected to submit the NDA in late 2026 or early 2027, with FDA approval projected for late 2027 or early 2028. Commercial launch likely in early 2028.

Why it matters: Retatrutide could reset the ceiling for what GLP-1 class medications can achieve. Nearly 30% average weight loss approaches what was previously only achievable through bariatric surgery.

CagriSema — Novo Nordisk's Combination

What it is: A fixed-dose combination of semaglutide (the active ingredient in Wegovy) and cagrilintide (a long-acting amylin analogue). Rather than targeting new receptors, CagriSema adds amylin — a pancreatic hormone that reduces appetite through a different mechanism than GLP-1. The theory: two distinct appetite-suppressing pathways working simultaneously.

The data: Phase 3 trials have shown approximately 25% average body weight loss, placing CagriSema between current approved options and retatrutide. Novo Nordisk submitted CagriSema for FDA approval, with a decision expected around October 2026.

Why it matters: If approved on schedule, CagriSema would be available before retatrutide — giving patients a >25% weight loss option potentially by early 2027. It's Novo Nordisk's answer to Eli Lilly's pipeline dominance, and it leverages their existing semaglutide manufacturing expertise.

Survodutide — The Liver Drug

What it is: A dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It's similar to retatrutide in targeting the glucagon receptor, but without the GIP component.

The data: Phase 2 data showed approximately 15% body weight loss plus significant liver fat reduction — making it particularly promising for people with metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). Phase 3 trial readouts are expected in the first half of 2026.

Timeline: If Phase 3 data is positive, NDA filing could happen in late 2026 or 2027, with potential approval in 2027-2028.

Why it matters: Survodutide could be the first GLP-1 class drug specifically positioned for fatty liver disease — a condition affecting roughly 30% of U.S. adults and currently lacking effective pharmacological treatment. The dual benefit of weight loss + liver fat reduction fills a major gap.

Amycretin / Zenagamtide — Novo Nordisk's Next Play

What it is: A single-molecule GLP-1/amylin agonist — essentially what CagriSema does with two compounds, amycretin tries to do with one. It's earlier in development than the other pipeline drugs.

The data: Phase 2 results are still emerging. Early data has been encouraging, but it's too soon for definitive efficacy numbers.

Timeline: Phase 2 ongoing. If successful, Phase 3 would start in 2027, with approval no earlier than 2028-2029.

Why it matters: It's Novo Nordisk's long-game hedge. If CagriSema succeeds, amycretin could be a next-generation simplification. If CagriSema stumbles, amycretin provides an alternative approach to the same biological target.

The Complete Pipeline Timeline

What This Means for You Right Now

If you're waiting for the "perfect" GLP-1 before starting treatment — stop waiting. Here's the pragmatic view:

The medications available today work. Wegovy and Zepbound are proven, available, and at historically low self-pay prices. Starting treatment now with a currently available drug doesn't prevent you from switching to a next-gen option when it becomes available.

Pipeline timelines are estimates, not guarantees. Drug development is unpredictable. The FDA can request additional data, safety signals can emerge, manufacturing delays can push launch dates. Retatrutide could be in pharmacies by 2028 — or it could be 2029.

Prices will keep dropping. The combination of pipeline competition, Medicare coverage expansion, manufacturer direct-to-consumer programs, and potential IRA-negotiated pricing (Ozempic at ~$274/month starting January 2027) means the financial trajectory is clearly downward.

The best GLP-1 medication is the one you can access, afford, and take consistently today. The pipeline is exciting. But it's the future — and your health is now.